Every morning, billions of people reach for a cup of coffee. For some, a single espresso provides a clean boost of alertness that lasts a few hours. For others, the same cup triggers a racing heart, hours of jitteriness, and sleep disruption long after the mug is empty. A significant part of this difference comes down to one gene: CYP1A2.
What CYP1A2 does
CYP1A2 encodes an enzyme in the cytochrome P450 superfamily — a group of liver enzymes responsible for metabolizing a wide range of compounds, from medications to dietary chemicals. CYP1A2 handles roughly 95% of the caffeine you consume, converting it through a series of steps into smaller metabolites that are eventually excreted.
The speed at which your CYP1A2 enzyme works determines how quickly caffeine clears your system. Faster clearance means caffeine's stimulant effects fade sooner. Slower clearance means caffeine accumulates — and its effects (and side effects) last longer.
The key variant: rs762551
The most studied variant in CYP1A2 is rs762551, also called 1F. People who carry the A allele at this position tend to be fast metabolizers; those with the C allele tend to be slow metabolizers. About half the population carries at least one C allele, making slow metabolism quite common.
A 2006 study published in JAMA found that among people with hypertension, slow metabolizers who drank four or more cups of coffee per day had a significantly higher risk of myocardial infarction compared with fast metabolizers. Fast metabolizers, by contrast, showed no increased risk — and some analyses suggested a mild protective association.
Beyond coffee
CYP1A2 also metabolizes several medications including clozapine, olanzapine, theophylline, and some antidepressants. If you are a slow metabolizer and take one of these drugs, the drug may accumulate to higher-than-expected levels, potentially increasing side effect risk. This is why CYP1A2 status is increasingly relevant in pharmacogenomics — the study of how genetics affects drug response.
What this means practically
If you are a fast CYP1A2 metabolizer, moderate coffee consumption is generally well tolerated. If you are a slow metabolizer, you may benefit from limiting caffeine intake — particularly if you have cardiovascular risk factors or are sensitive to stimulants. That said, CYP1A2 is one factor among many; lifestyle, other genetic variants, and individual health status all play a role.
Vogelview reports your CYP1A2 rs762551 genotype with an evidence level of Established — one of the most robustly replicated pharmacogenomic findings in the consumer testing space.